玉溪好的医院做人流玉溪最好的人流医院是哪家,玉溪正规人流多少钱,玉溪那里做引产好,玉溪做人流大约多少钱,玉溪市看人流的医院,玉溪人流哪个医院靠谱,玉溪引产哪家医院好

CHICAGO, Jan. 21 (Xinhua) -- Chinese President Hu Jintao left Chicago for home on Friday after concluding a four-day state visit to the United States, during which Hu and his U.S. counterpart Barack Obama agreed to build a China-U.S. cooperative partnership based on mutual respect and mutual benefit.President Hu, who began his visit on Tuesday, had extensive and in-depth discussions with Obama at the White House on Wednesday on major bilateral, regional and world issues.The two sides reached "important agreement on China-U.S. relations and major international and regional issues of shared interest," the Chinese president said when he and Obama met the press following their discussions."We both agree to further push forward the positive, cooperative and comprehensive China-U.S. relationship," Hu said, adding that both sides also pledged to forge "a China-U.S. cooperative partnership based on mutual respect and mutual benefit" for the benefit of the two countries and beyond.The Chinese president said he and Obama also discussed some disagreements in the economic and trade area, with both sides pledging "to continue to appropriately resolve these according to the principle of mutual respect and consultation on an equal footing."Also on Wednesday, Hu attended a state dinner and a welcome ceremony hosted by Obama.Hu told the Americans on several occasions in Washington that the purpose of his visit to the United States was "to increase mutual trust, enhance friendship, deepen cooperation and advance the positive, cooperative and comprehensive China-U.S. relationship for the 21st century."During Hu's visit, the two countries issued the "China-U.S. Joint Statement," which says "China and the United States committed to work together to build a cooperative partnership based on mutual respect and mutual benefit in order to promote the common interests of both countries and to address the 21st century's opportunities and challenges.""China and the United States are actively cooperating on a wide range of security, economic, social, energy, and environmental issues which require deeper bilateral engagement and coordination," the statement said.On Thursday, Hu called upon the U.S. Congress to continue helping the two countries boost their relations.Pursuing a healthy and steady development of China-U.S. ties is China's established policy and strategic choice, Hu stressed when meeting House Speaker John Boehner and Senate Majority Leader Harry Reid.Also on Thursday in Washington, Hu delivered an important speech at the welcome luncheon hosted by friendly organizations in the United States.To advance the sustained, sound and steady development of China-U.S. relations serves the fundamental interests of peoples of China and the United States, he said.

SAN FRANCISCO, March 20 (Xinhua) -- Boeing's 747-8 Intercontinental took to the sky for the first time on Sunday, a milestone for the U.S. aviation giant's latest and biggest passenger plane.Live webcast by Boeing showed that a 747-8 Intercontinental touched down at around 2:25 p.m. PST (2125 GMT) Sunday at the Boeing Field airport in Seattle in the U.S. states of Washington, after wrapping up the airplane's inaugural flight that lasted about four and half hours.During the test flight, the pilots did some system and function checks and everything went fine, according to the webcast.The new 747-8 Intercontinental can carry 467 passengers in a three-class configuration, said Boeing, which touted the new wide- body jet airliner as the only airplane in the 400-500 seat market.The Boeing 747-8 Intercontinental takes off on its maiden flight from Paine Field, in Everett, Washington, March 20, 2011. The 747-8 Intercontinental willseat 467 passengers, 51 more than the latest model of the classic 747, and burn less fuel while offering passengers more comfort, the U.S. planemaker says.Using 787-technology GEnx engines, the airplane will be quieter, produce lower emissions and achieve better fuel economy for airlines, Boeing said.The airplane also features a new wing design and an upgraded flight deck. Its interior incorporates features from the Boeing 787 Dreamliner including a new curved, upswept architecture that will give passengers a greater sense of space and comfort, while adding more room for personal belongings.Boeing has noted that compared with its predecessor, the 747- 400, the 747-8 Intercontinental provides 16 percent better fuel economy, 16 percent less carbon emissions per passenger and generates 30 percent smaller noise footprint, while carries 51 more passengers.Boeing in February said that Korean Air, VIP customers and launch customer Lufthansa have ordered a total of 33 747-8 passenger planes, with the first delivery scheduled for the fourth quarter of this year.It is reported that the 747-8 Intercontinental has a list price of about 317 million U.S. dollars.Earlier in March, Boeing announced that it has signed an agreement with Air China for the purchase of five 747-8 Intercontinental jetliners.

BEIJING, May 23 (Xinhuanet) -- A new study suggests that crossing your arms could reduce the intensity of pain, according to media reports.The study was conducted by researchers from University College London (UCL), who reported their finding in the journel Pain.They said that crossing the arms could confuse the brain and conflicting information between the brain's two maps - one for the person's body and the other for external space - leading to a lower sensation of pain.A laser was used to generate a four millisecond pin prick on the hands of eight volunteers, who experienced this twice with their arms at their sides and arms crossed.Then the participants were asked to rate the intensity of pain in two situations and an EEG (electroencephalography) was used to measure their electrical brain responses.The results showed that both the perception of pain and EEG activity was reduced when the arms were crossed."Perhaps when we get hurt, we should not only 'rub it better' but also cross our arms," said Giandomenico Iannetti of UCL's department of physiology, pharmacology and neuroscience.

LOS ANGELES, March 3 (Xinhua) -- More and more American adults are suffering from a decline in overall sleep duration, the U.S. Centers for Disease Control and Prevention (CDC) said on Thursday.It's recommended that adults should sleep seven to nine hours a night to maintain good health, but more than one-third of Americans do not meet that requirement, according to the CDC.Insufficient sleep poses a long-term heath threat and impairs work performance and the ability to drive safely, the CDC said.Chronic sleep loss also is associated with obesity, increased risk of death and other health problems, according to the CDC."Over the last 20 years there has been a decline in overall sleep duration in adults," said Lela McKnight-Eily, a clinical psychologist and epidemiologist at the CDC's National Center for Chronic Disease Prevention."Within our culture there seems to be a belief that sleep isn't a part of overall essential health," she said.McKnight-Eily and her colleagues studied the sleep habits of 74,571 adults in 12 states, 35.3 percent reported sleeping less than seven hours.In addition, 48 percent reported snoring, 37.9 percent said they fell asleep at least once during the day the previous month and 4.7 percent admitted to falling asleep at the wheel at least once.Drowsiness or nodding off while driving accounts for 1,550 deaths and 40,000 injuries a year, according to the U.S. Department of Transportation.To get enough sleep, Americans have to change lifestyle habits, including longer workdays and late nights on the computer, McKnight-Eily said, noting that too much screen time paring away much-needed sleep time.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.